Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Q4 FY26 Earnings Presentation
26 slides from Onesource Specialty Pharma's earnings presentation, May 13, 2026
Slide 1: Exchange filing cover letter
Corporate Office: Registered Office: Star 1, Opp IIM Bangalore, Bilekahalli, Cyber One, Unit No. 902, Sector 30A, Bannergha a Road, Bengaluru – Plot No - 4 & 6, Vashi, 560076, India Navi Mumbai - 400703, India T: +91 80 6784 0738 T: +91 22 2789 2924 Date: May 13, 2026 BSE Limited National Stock Exchange
Slide 2: OneSource Announces FY26 Results with Strong Q4 Performance; Reaffirms FY28 Guidance
Press Release May 13, 2026 OneSource Announces FY26 Results with Strong Q4 Performance; Reaffirms FY28 Guidance Revenue up 47% QoQ and EBITDA expanding more than 5x, supported by broad business momentum and India semaglutide launches Performance Highlights • Revenues at ₹4,282 million, up 47% QoQ, d
Slide 3: About OneSource Specialty Pharma Limited
Press Release May 13, 2026 About OneSource Specialty Pharma Limited OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-dev
Slide 4: Investor Presentation | Q4 & FY26
Investor Presentation | Q4 & FY26 May 13th, 2026
Slide 5: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 6: Financial Performance
Financial Performance ONe€SOUICE
Slide 7: Q4FY26 Performance Snapshot
Strong revenue and EBITDA recovery in Q4 driven by growth across all service offerings and semaglutide India launches; Canada semaglutide approvals in place, supporting continued momentum into FY27 ( Q4FY26 Performance Snapshot ) ₹4,282m Revenue “We saw a strong recovery in Q4 driven by broad-based
Slide 8: Q4FY26 delivers sequential revenue and EBITDA growth as commercialisation gains momentum
Q4FY26 delivers sequential revenue and EBITDA growth as commercialisation gains momentum In $ m Q4FY26 Q3FY26 QoQ Q4FY25 Financial Snapshot Revenue 47.6 32.3 47% 47.4 • Revenue of $47.6m/₹4,282m, up 47% QoQ EBITDA 10.2 1.9 5x+ 20.3 reflects a strong recovery driven by growth EBITDA margin (%) 21% 6%
Slide 9: FY26 a transition year; expanding capability and capacity to deliver FY27 growth
FY26 a transition year; expanding capability and capacity to deliver FY27 growth driven by commercial launches In $ m FY26 FY25 YoY Financial Snapshot Revenue 158.1 160.7 (2%) • Full-year revenue declined marginally by 2% EBITDA 33.8 51.9 (35%) YoY, reflecting a softer second half impacted by EBITDA
Slide 10: Business & Operational Updates
Business & Operational Updates FY26
Slide 11: Added new customers, deepened relationships, and expanded market reach across all service offerings
Added new customers, deepened existing relationships, and expanded market reach across all service offerings FY26 at a Glance 31 18 5 10 70+ 49 New MSAs and Licensing Injectable and softgel New logos added, NBE (1) / NCE-1 (9) Active RFPs Successful Regulatory agreements signed product launches brin
Slide 12: Strong and diverse customer base, well positioned to ride the semaglutide wave
With a strong and diverse customer base, well positioned to ride the semaglutide wave across available markets First semaglutide approvals secured in Canada; products already marketed in India Top off-patent semaglutide markets (by size)1 OneSource customers (#) #1 Global Leaders Regional Players Co
Slide 13: DDC momentum driven by early mover advantage, multi-market presence, and growing partner network
DDC momentum driven by early mover advantage, multi-market presence, and growing partner network First & only CDMO 3 3 11 50+ G7 Semaglutide GLP-1 Device DDC approvals molecules1 Platforms Projects Semaglutide India Multiple partners approved; Product in market from Day 1 LAUNCHED Canada 1st approva
Slide 14: Capacity build-out progressing on track to support upcoming commercial supply
Capacity build-out progressing on track to support upcoming commercial supply 2nd line at flagship site under qualification with commercial readiness by Q2FY27 • Cartridge capacity expansion in full swing at our flagship site o ~$80m committed to date against a total announced capex of $100m; 380+ h
Slide 15: Biologics business emerging as next growth engine with strong industry tailwinds
Biologics business emerging as next growth engine with strong industry tailwinds and growing customer funnel FY26 at a Glance 4x 2nd 1 1 KL 4 KL Project signed with Top 3 global of the few integrated DS- DP site Installed microbial capacity Installed mammalian capacity Increase in Biologics funnel (
Slide 16: Injectables and Softgels continue to witness strong traction
Injectables and Softgels continue to witness strong traction driven by licensing deals as well as CDMO opportunities FY26 at a Glance 10+ 15+ 35+ Top 5 2.4 Approved and on market product in Sterile Penicillin manufacturer for US billion installed softgel capsules New licensing and CDMO deals New com
Slide 17: Continued exemplary quality and compliance track record across all sites
Continued exemplary quality and compliance track record across all sites OVERALL TRACK RECORD FY26 HIGHLIGHTS 210+ Successful audits 100% GMP inspection USFDA EIR Received — Flagship site since inception success rate Establishment Inspection Report (EIR) received following Mar 2025 inspection, valid
Slide 18: ESG progress validated with ratings and recognition
ESG progress validated with ratings and recognition Latest Rating Updates Rewards & Recognition NSE Sustainability Ratings & Analytics 73/100 Received the Sustainability Excellence Award at the 5th National Sustainability Excellence Award “Leader” category among NSE-listed peers Bharat CSR & Sustain
Slide 19: Updates on Announced Acquisition and Business Outlook
Updates on Announced Acquisition and Business Outlook FY26
Slide 20: Proposed acquisition of Steriscience assets paused – to re-engage post FY28
Proposed acquisition of two USFDA-approved specialty injectable assets from Steriscience paused – to re-engage post FY28 • Scheme of arrangement announced in September 2025. Swap ratios based on independent valuation by PwC and independent fairness opinion from ICICI Securities • On 26 February 2026
Slide 21: Reaffirming FY28 outlook of $400 million organic revenue, ~40% EBITDA margin
Reaffirming FY28 outlook of $400 million organic revenue, ~40% EBITDA margin supported by strong execution and business levers 400M USD 40% >50% Revenue (organic) Steady state EBITDA margin Targeted ROCE1 All businesses to contribute to FY28 delivery, with operating leverage amplifying the financial
Slide 22: Q4FY26 earnings call details
Q4FY26 May Day: Wednesday 13 Schedule: Date: 13th May 2026 Time: 03:00 PM IST Arun Kumar, Founder & Non-Executive Chairperson Speakers: Neeraj Sharma, CEO & MD Anurag Bhagania, CFO +91 22 6280 1372 Dial In: +91 22 7115 8193 Diamond Pass: Click here for early registration
Slide 23: OneSource at a glance
OneSource at a glance
Slide 24: Building a pure-play CDMO platform, distinguished by extensive capabilities and robust financial metrics
Building a pure-play CDMO platform, distinguished by extensive capabilities and robust financial metrics ROBUST MANUFACTURING & PRESENCE ACROSS HIGHLY ATTRACTIVE EXPERT PROFESSIONALS AND ONE-OF-ITS-KIND COMPLIANCE TRACK RECORD MODALITIES INCLUDING GLP-1 FINANCIAL PROFILE SEASONED BOARD #1 5 Multiple
Slide 25: Industry-leading capacities backed by stellar compliance record
Industry-leading capacities backed by stellar compliance record Drug-device combinations Biologics development centre Sterile Injectables Soft gelatin capsules1 Penicillin fill-finish Integrated Biologics and Drug Products site Area (Sq ft) 450,000 100,000 70,000 60,000 42,000 Microbial: 1x1KL SS Ca
Slide 26: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, I
OneSource Specialty Pharma — Q4 FY26 Earnings Presentation on 6ix